title: The significance of an isolated central nervous system relapse, occurring as first relapse in children with acute lymphoblastic leukemia.
abstract: In a retrospective study, which comprised the whole Dutch childhood population of approximately 3 million children, the authors assessed the influence of an isolated meningeal relapse, occurring as first relapse, together with some patient and treatment characteristics on prognosis in 142 children with acute lymphoblastic leukemia (ALL). Until their first relapse, patients were initially treated according to standard protocols, whereas the treatment for relapse was heterogeneous. Concerning the probability of achieving a second complete remission (CR) it appears that the duration of the first CR is the single most important prognostic factor. The duration of the first CR is also the most important factor with regard to the duration of the second CR, upon which also age and sex have a significant influence. Concerning the survival from the time of central nervous system (CNS) relapse, again the duration of the first CR appears to be the most important prognostic factor, followed by age and the institution of systemic reinduction treatment. Other factors, such as initial leukocyte count, attainment of first CR within 48 days, type of reinduction treatment, and the cerebral spinal fluid (CSF) blast count at the time of relapse, have a less important, but nevertheless significant influence on survival. The median survival from the time of CNS relapse is 25 months, the 5-year survival is 25%, whereas the ultimate survival will be less than 20%. From 90 patients who developed second or subsequent relapses, 75% experienced a bone marrow relapse during the follow-up period. From this study the authors conclude that CNS relapse in children with ALL carries a grave prognosis, which requires the institution of intensive retreatment programs.
authors.affiliation: Werkgroep Kindertumoren, Emma Kinderziekenhuis and Antoni van Leeuwenhoekhuis, Amsterdam.
authors.forename: H
authors.initials: H
authors.lastname: Behrendt
authors.forename: E F
authors.initials: EF
authors.lastname: van Leeuwen
authors.forename: C
authors.initials: C
authors.lastname: Schuwirth
authors.forename: R J
authors.initials: RJ
authors.lastname: Verkes
authors.forename: J
authors.initials: J
authors.lastname: Hermans
authors.forename: A
authors.initials: A
authors.lastname: van der Does-van den Berg
authors.forename: E R
authors.initials: ER
authors.lastname: van Wering
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008577:Meningeal Neoplasms / Q000401:mortality / Q000517:prevention & control / Q000532:radiotherapy / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000517:prevention & control / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000517:prevention & control / Q000532:radiotherapy / Q000628:therapy; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D008727:Methotrexate